Recently, glioma-specific antigens assessed in preclinical studies have shown potential anti-glioma effects, such as epidermal growth factor receptor variant III (EGFRvIII) [29], human epidermal growth factor receptor 2 (HER2) [30], and erythropoietin-producing hepatocellular carcinoma A2 (EphA2) [31]. The gene discussed is EPO; the disease is glioma.